xenoport inc (XNPT) Key Developments
XenoPort, Inc. Announces Initiation of Phase 2 Clinical Trial of XP23829 in Patients With Psoriasis
Jun 23 14
XenoPort, Inc. announced that it has initiated a Phase 2 clinical trial of XP23829, its proprietary investigational next-generation fumaric acid product candidate. The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of XP23829 as a potential treatment of patients with moderate-to-severe chronic plaque-type psoriasis. XenoPort expects to enroll approximately 200 subjects in this trial, which is being conducted in the United States. The study will include a screening and washout phase of up to four weeks, a 12-week treatment phase and a four-week post-treatment phase. Eligible study subjects will be randomized to placebo or one of three treatment arms of XP23829: 400 mg or 800 mg once daily or 400 mg twice daily. The primary endpoint of the study will examine the percent change in Psoriasis Area and Severity Index (PASI) score from baseline at the end of week 12. Secondary endpoints will include the proportion of subjects who achieve a reduction of 75% or greater from baseline in PASI (PASI-75) score and subjects who achieve a Static Physicians Global Assessment (sPGA) score of clear or almost clear.
Xenoport, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 04:30 PM
May 21 14
Xenoport, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 04:30 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Ronald W. Barrett, Co-Founder, Chief Executive Officer and Director.
Reckitt Benckiser Pharmaceuticals and XenoPort Enter into Global Licensing Agreement for Arbaclofen Placarbil
May 15 14
Reckitt Benckiser Pharmaceuticals Inc. and XenoPort, Inc. announced that they have entered into a license agreement pursuant to which Reckitt Benckiser Pharmaceuticals will be granted exclusive worldwide rights for the development and commercialization of XenoPort's clinical-stage oral product candidate arbaclofen placarbil for all indications. Arbaclofen placarbil is a patent protected new chemical entity that Reckitt Benckiser Pharmaceuticals plans to advance into a Phase IIB proof-of-concept study for the treatment of alcohol use disorders - a condition affecting more than 140 million people worldwide. Alcohol use disorders are a global public health issue, with an annual economic burden of $224 billion in the United States alone. Alcoholism is directly responsible for more than 2.5 million deaths each year and is a causal factor in over 60 other major types of disease. The current treatment approach is predominantly psychosocial support and is largely non-medicalized. The majority of healthcare professionals feel underequipped to manage patients with substance abuse - including alcoholism - based on currently available standards of care.Arbaclofen placarbil will be tested for its ability to suppress alcohol cravings, reduce alcohol intake and to possibly facilitate maintenance of abstinence in alcohol dependent people. In prior clinical trials, arbaclofen placarbil has demonstrated attributes that may enable convenient dosing, stable plasma exposure and good tolerability. Under the terms of the agreement, Reckitt Benckiser Pharmaceuticals will receive exclusive rights to develop and commercialize arbaclofen placarbil worldwide for all indications, subject to certain rights by XenoPort to negotiate with Reckitt Benckiser Pharmaceuticals on collaborations for non-addiction indications. In exchange for these rights and upon effectiveness of the agreement, XenoPort is entitled to receive an up-front, non-refundable cash payment of $20 million and another $5 million upon the transfer of certain technology and materials to Reckitt Benckiser Pharmaceuticals. XenoPort also will be eligible to receive aggregate cash payments of up to $70 million upon the achievement by Reckitt Benckiser Pharmaceuticals of certain development and regulatory milestones, as well as up to $50 million for commercial milestones. In addition, XenoPort is entitled to receive tiered double-digit royalty payments up to the mid-teens on a percentage basis on potential future net sales of arbaclofen placarbil in the United States and high single-digit royalty payments on potential future net sales outside the United States.
XenoPort, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2014
May 8 14
XenoPort, Inc. reported unaudited earnings results for the first quarter ended March 31, 2014. Revenues for the quarter were $3.4 million, compared to $0.5 million for the same period in 2013. Loss from operations was $20.5 million against $23.6 million last year. Net loss for the first quarter was $20.5 million or $0.36 per basic and diluted share, compared to net loss of $23.5 million or $0.50 per basic and diluted share for the same period in 2013. The increase in revenues for the first quarter of 2014 was principally due to HORIZANT net product sales. HORIZANT net product sales totaled $3.0 million for the three months ended March 31, 2014.
Xenoport, Inc. to Report Q1, 2014 Results on May 08, 2014
May 1 14
Xenoport, Inc. announced that they will report Q1, 2014 results at 4:30 PM, US Eastern Standard Time on May 08, 2014